Careview Communications (OTCMKTS:CRVW - Get Free Report) and Fulgent Genetics (NASDAQ: FLGT - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations. Institutional and Insider Ownership 48.1% of Fulgent Genetics
Fulgent is set to buy Bako Diagnostics assets and StrataDx for $55.5M, expanding into anatomic pathology and dermatopathology to scale lab services.
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it has entered into a definitive agreement to acquire selected assets of Bako Diagnostics (“Bako”), a premier pathology laboratory headquartered in Alpharetta, GA and to acquire StrataDx, a premier dermatopathology laboratory located in Lexington, MA. Fulgent will acquire.
Fulgent Genetics (NASDAQ: FLGT - Get Free Report) and Patient Portal Technologies (OTCMKTS:PPRG - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership. Risk and Volatility Fulgent Genetics has
Fulgent Genetics, Inc. ( FLGT ) UBS Global Healthcare Conference 2025 November 10, 2025 5:00 PM EST Company Participants Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief Financial Officer Conference Call Participants Lu Li - UBS Investment Bank, Research Division Presentation Lu Li UBS Investment Bank, Research Division Great. Well, our next session is the management team from Fulgent Genetics.
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that members of its management team are scheduled to present at the following upcoming investor conferences: UBS Global Healthcare Conference on Monday, November 10th at 5:00 PM Eastern Time Piper Sandler 37th Annual Healthcare Conference on Tuesday, December.
Fulgent Genetics, Inc. ( FLGT ) Q3 2025 Earnings Call November 7, 2025 8:30 AM EST Company Participants Ming Hsieh - Chairman & CEO Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief Financial Officer Conference Call Participants Lauren Sloane - The Blueshirt Group, LLC Lu Li - UBS Investment Bank, Research Division David Westenberg - Piper Sandler & Co., Research Division Andrew Cooper - Raymond James & Associates, Inc., Research Division Presentation Operator Greetings, and welcome to the Fulgent Genetics Q3 2025 Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.
Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of a loss of $0.24 per share. This compares to earnings of $0.31 per share a year ago.
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2025. Third Quarter 2025 Results: Revenue of $84.1 million, growing 17% year-over-year GAAP loss of $6.6 million, or ($0.21) per share Non-GAAP income of $4.5 million, or $0.14 per share Adjusted EBI.
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced preliminary clinical data as of September 25, 2025, the preliminary data cutoff from its ongoing phase 2 clinical trial investigating FID-007 in combination with cetuximab in ≤ 2nd line treatment of patients diagnosed with recurrent or metastatic head and neck.
